Clinical Development Programs

We are currently conducting or have completed clinical trials of our proprietary HuCNS-SC® product candidate (purified human neural stem cells) in spinal cord injury and in two fatal neurodegenerative disorders:

  • Spinal Cord Injury

    In December 2010, we received authorization from Swissmedic, the Swiss regulatory agency for therapeutic products, to initiate a Phase I/II clinical trial of our HuCNS-SC cells in chronic spinal cord injury. The trial initiated in March 2011 and is currently open for enrollment.  The trial is being conducted in Switzerland at the Balgrist University Hospital, University of Zurich. Learn more…

  • Pelizaeus-Merzbacher Disease (PMD)

    In November 2009, we initiated a Phase I trial of our HuCNS-SC cells in PMD, a myelination disorder that primarily affects young children.  The trial is being conducted at the University of California, San Francisco (UCSF) Benioff Children's Hospital. Learn more…

  • Neuronal Ceroid Lipofuscinosis (NCL or Batten Disease)

    In January 2009, we completed a Phase I clinical trial of our HuCNS-SC cells in NCL, a lysosomal storage disorder in children. The trial was conducted at Oregon Health & Science University (OHSU) Doernbecher Children’s Hospital, a leading medical center with nationally recognized programs in pediatric neurology and neurosurgery. Learn more…

We believe that the human safety data we are accumulating for our HuCNS-SC cells through these clinical trials will facilitate the pathway for future clinical testing in other central nervous system (CNS) disorders, including retinal degenerative diseases such as age-related macular degeneration and retinitis pigmentosa.

Additional information about our clinical trials can be found at the US National Institutes of Health Clinical Trials website.

 

 

 

Back to Top

    Nalin Gupta MD, PhD, Chief of Pediatric Neurological Surgery at UCSF Benioff Children’s Hospital, performing the first transplantation of StemCells HuCNS-SC® product candidate in our Phase I PMD trial. This landmark clinical trial marks the first time that human neural stem cells have been transplanted as a potential treatment for a myelination disorder.

    Photo courtesy of UCSF

    Patient Enrollment

    We are currently screening and enrolling patients in our spinal cord injury trial.

    Learn more…

    Please Note

    You are about to open a web page or document that is hosted by a third party and is not maintained by StemCells, Inc. and to which our Privacy Policy does not apply.

    This link is provided to you for convenience and does not serve as an endorsement by StemCells, Inc. of any information or contacts that you may find on this third party site.

    Cancel | Continue

    X

    Please Note!

    You are about to open a web page or document that is hosted by a third party and is not maintained by StemCells, Inc. and to which our Privacy Policy does not apply.

    This link is provided to you for convenience and does not serve as an endorsement by StemCells, Inc. of any information or contacts that you may find on this third party site.

    Cancel | Continue

    X